Table 1.

Basic characteristics of the included studies

Study	Year	Cancer type	Country	Study type	Study period	No. of cases	Male patients, n (%)	Age, years	Survival type	Treatment	Stage	ALI cutoff value	Cutoff selection method
Jafri et al. [25]	2013	NSCLC	USA	R	2000–2011	173	116 (67%)	57 (34–88)	OS, PFS	No surgery	Metastatic	18.4	ROC curve analysis
He et al. [29]	2015	SCLC	China	R	2006–2011	365	310 (84.9%)	59 (22–82)	OS	No surgery	Mixed	19.50	Cutoff Finder
Kim et al. [30]	2016	SCLC	Korea	R	2010–2015	186	156(83.9%)	68.9 ± 9.4	OS	No surgery	Mixed	31.1	Cutoff value
Park et al. [31]	2017	Diffuse large B cell lymphoma	Korea	R	2006–2014	212	142 (67%)	59 (26–76)	OS, PFS	No surgery	Mixed	15.5	ROC curve analysis
Bacha et al. [32]	2017	NSCLC	France	R	2010–2012	41	41 (100%)	55 (41–76)	OS	No surgery	Metastatic	23.2	ROC curve analysis
Kobayashi et al. [33]	2018	NSCLC	Japan	R	2009–2014	166	74 (44.6%)	–	OS	Surgery	Non-metastatic	22.2	ROC curve analysis
Tomita et al. [34]	2018	NSCLC	Japan	R	2008–2012	341	173 (50.7%)	69 (median)	OS	Surgery	Non-metastatic	37.66	Cutoff Finder
Shibutani et al. [35]	2019	Colorectal cancer	Japan	R	2008–2016	159	87 (54.7%)	65 (18–89)	OS	No surgery	Metastatic	28.9	ROC curve analysis
Jank et al. [36]	2019	Head and neck squamous cell carcinoma	Austria	R	2002–2012	93	72 (77.4%)	58 (27–72)	OS, DFS	Surgery	Mixed	37.6	Cutoff value

Abbreviations: NSCLC non-small cell lung cancer, SCLC small cell lung cancer, R retrospective, OS overall survival, PFS progression-free survival, DFS disease-free survival, Mixed included patients with metastatic and non-metastatic disease, ALI advanced lung cancer inflammation index, ROC receiver operating characteristic curve